Cargando…

Synthesis and biological evaluation of [(131)I]iodocarvedilol as a potential radiopharmaceutical for heart imaging

The optimization of the radiolabeling yield of carvedilol with iodine-131 was described. Dependence of the labeling yield of [(131)I]iodocarvedilol on the concentration of carvedilol, chloramine-T content, pH of the reaction mixture and reaction time was studied in details. Carvedilol was labeled wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Motaleb, M. A., Attalah, K M, Shweeta, H A, Ibrahim, I. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018969/
https://www.ncbi.nlm.nih.gov/pubmed/36922888
http://dx.doi.org/10.1186/s13065-023-00935-0
Descripción
Sumario:The optimization of the radiolabeling yield of carvedilol with iodine-131 was described. Dependence of the labeling yield of [(131)I]iodocarvedilol on the concentration of carvedilol, chloramine-T content, pH of the reaction mixture and reaction time was studied in details. Carvedilol was labeled with iodine-131 at pH 6 with a labeling yield of 92.6 ± 2.77% by using 100 µg carvedilol, 200 µg chloramin-T (CAT) and 30 min reaction time. The formed [(131)I]iodocarvedilol was nearly stable for a time up to one day. Biodistribution of [(131)I]iodocarvedilol was investigated in experimental animals. [(131/123)I]iodocarvedilol was located in the heart with a concentration of 19.6 ± 0.41% of the injected dose at 60 min post injection. It has a high heart uptake and heart to liver ratio, both of which are beneficial for high-quality SPECT (single-photon emission computerized tomography) myocardial imaging. [(131/123)I]iodocarvedilol solve most the drawbacks of the FDA (Food and Drug Administration) approved (99m)Tc-sestamibi.